Answers are grounded in this paper and cite their sources.
Dose-dense induction followed by HDT/ASCT was well tolerated and led to long-term PFS in 44% of treatment-naive patients with PTCL. This represents an encouraging outcome, particularly considering the high median age and adverse risk profile of the study population. Therefore, dose-dense induction and HDT/ASCT are a rational up-front strategy in transplantation-eligible patients with PTCL.
No takes yet. Share an insight, caveat, or question.
d’Amore et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: